Preferential Localization of a Vesicular Monoamine Transporter to Dense Core Vesicles in PC12 Cells

Yongjian Liu,* Erik S. Schweitzer,** Melissa J. Nirenberg,** Virginia M. Pickel,** Christopher J. Evans,* and Robert H. Edwards*

Departments of *Neurology and Biological Chemistry,**Anatomy & Cell Biology, and *Psychiatry; Molecular Biology Institute, UCLA School of Medicine, Los Angeles, California 90024-1769; and **Department of Neurology and Neuroscience, Cornell University Medical College, New York 10021

Abstract. Neurons and endocrine cells have two types of secretory vesicle that undergo regulated exocytosis. Large dense core vesicles (LDCVs) store neural peptides whereas small clear synaptic vesicles store classical neurotransmitters such as acetylcholine, γ-aminobutyric acid (GABA), glycine, and glutamate. However, monoamines differ from other classical transmitters and have been reported to appear in both LDCVs and smaller vesicles. To localize the transporter that packages monoamines into secretory vesicles, we have raised antibodies to a COOH-terminal sequence from the vesicular amine transporter expressed in the adrenal gland (VMAT1). Like synaptic vesicle proteins, the transporter occurs in endosomes of transfected CHO cells, accounting for the observed vesicular transport activity. In rat pheochromocytoma PC12 cells, the transporter occurs principally in LDCVs by both immunofluorescence and density gradient centrifugation. Synaptic-like microvesicles in PC12 cells contain relatively little VMAT1. The results appear to account for the storage of monoamines by LDCVs in the adrenal medulla and indicate that VMAT1 provides a novel membrane protein marker unique to LDCVs.

Neurotransmitters are stored in secretory vesicles that undergo regulated exocytosis. Peptide transmitters enter the secretory compartment by co-translational translocation of a precursor protein into the lumen of the endoplasmic reticulum and subsequently undergo processing and packaging into mature vesicles (de Camilli and Jahn, 1990; Trimble et al., 1991; Kelly, 1991). In contrast, the synthesis of classical transmitters such as acetylcholine, γ-aminobutyric acid (GABA), glycine, glutamate, and the biogenic amines occurs in the cytoplasm. These transmitters also appear in the cytoplasm after removal from the synapse by specific plasma membrane reuptake systems (Amara and Kuhar, 1993). Thus, classical transmitters require specific transport from the cytoplasm for packaging into secretory vesicles. In addition, the storage of neural peptides and classical transmitters occurs in distinct vesicle populations.

Neural cells store peptide transmitters in large dense core vesicles (LDCVs), the functional equivalent of the secretory granules in which endocrine cells store peptide hormones (Kelly, 1991; Trimble et al., 1991). These granules range in size from 40 to over 100 nm and have a characteristic dense core in electron micrographs, presumably due to their protein content. LDCVs also have a relatively diffuse distribution in the cytoplasm. They appear in nerve terminals but not at the same high density as classical synaptic vesicles; they also occur in the cell body and dendrites. In contrast, neurons store classical transmitters such as acetylcholine, GABA, glycine, and glutamate in small clear synaptic vesicles of 40-50 nm (Sudhof and Jahn, 1991; Edwards, 1992). Typical synaptic vesicles cluster in large numbers at the nerve terminal, in close proximity to the presynaptic membrane. In addition to these differences in structure and localization, large dense core vesicles and synaptic vesicles also differ in function. Exocytosis from LDCVs occurs with a longer latency after stimulation than exocytosis from synaptic vesicles (de Camilli and Jahn, 1990). The observed differences in rate of release presumably account for the relatively prolonged action of peptides as neural modulators and the more rapid action of classical neurotransmitters in direct signaling. In addition, high frequency stimulation favors release from LDCVs relative to synaptic vesicles (Andersson et al., 1982). Differential sensitivity to α-latrotoxin (Meioli et al., 1988), and intracellular calcium (Rane et al.,...
transmitters in different vesicular compartments has clear implications for the regulation of their release and for their role in synaptic transmission. Since the packaging of classical transmitters into vesicles requires transport from the cytoplasm, the selective packaging of specific transmitters into different types of vesicles depends on the expression of specific transport activities by these different vesicles.

Previous studies have identified at least four distinct vesicular transport activities: one for the biogenic amines, a second for acetylcholine, another for GABA and glycine and a fourth for glutamate (Sudhof and Jahn, 1991; Edwards, 1992). The availability of bovine adrenal chromaffin granules and their robust transport activity have made the vesicular transport of monoamines a prototype for vesicular neurotransmitter transport. Studies using this preparation have shown that vesicular amine transport depends on a pH gradient generated by the vesicular H+-ATPase (Kanner and Schuldiner, 1987; Johnson, 1988). The transporter exchanges two luminal protons for a cytoplasmic amine. Recent studies have shown that the vesicular transporters for other classical transmitters depend on different aspects of the same H+-electrochemical gradient (Anderson et al., 1982; Maycox et al., 1988; Hell et al., 1990). However, classical transporters do not all appear to be stored in the same vesicular compartment. Typical small synaptic vesicles express specific transport activities for acetylcholine, GABA, glycine, and glutamate, consistent with storage in this compartment (Burger et al., 1989). On the other hand, cells in the adrenal medulla store monoamines with neural peptides in large dense core chromaffin granules (Johnson, 1988). In the central nervous system, neurons store monoamines in small vesicles that may contain a dense core depending on the method of fixation (Smith, 1972; Thureson-Klein, 1983). Thus, the storage of monoamines appears to differ from that of other classical transmitters and presumably reflects the differential sorting of vesicular transport proteins.

Using selection in the neurotoxin N-methyl-4-phenylpyridinium (MPP+), we have recently cloned a cDNA encoding the chromaffin granule amine transporter (CGAT) or vesicular amine transporter (VMAT1) (Liu et al., 1992b; Erickson et al., 1992). The transporter protects against this toxin by sequestering it in intracellular vesicles, away from its primary site of action in mitochondria (Liu et al., 1992a). The sequence predicts a protein with twelve transmembrane domains and weak homology to several bacterial antibiotic resistance transporters (Liu et al., 1992b). We have now used the amino acid sequence deduced from this cDNA to design a synthetic peptide, produce polyclonal antisera to the transporter and determine its intracellular location. The results indicate expression of the transporter in endocytic vesicles of CHO fibroblasts and preferential expression in LDCVs of neuro-endocrine PC12 cells.

### Material and Methods

#### Cell Culture

CHO cells were maintained in Ham's F12 medium with 5% FCS and rat pheochromocytoma PC12 cells in modified DME with 10% horse serum and 5% FCS. All cultures were kept at 37°C in 5% CO2 and all media contained penicillin and streptomycin.

CHO cells were co-transfected as previously described (Liu et al., 1992a) with 10 µg of the VMAT1 cDNA in the plasmid expression vector CDM8 and 1 µg of the selectable marker Rous sarcoma virus-neomycin (RSV-neo) per 10 cm plate. After initial selection in 400 µg/ml G418 for 2 wk, the cells were selected again in 1 mM MPP+ for at least 3 wk. MPP+ resistant (mpp+) cells were maintained in the absence of the toxin for at least 1 wk before study.

To label the dense core granules with [3H]norepinephrine, PC12 cells were incubated in standard medium containing 5 µCi [3H]noradrenaline (Amersham Corp., Arlington Heights, IL/25 ml for at least 6 h before cell fractionation.

### Peptide Synthesis and Antibody Production

The peptide CGENSDPSGGE was synthesized manually and coupled to keyhole limpet hemocyanin (KLH) through the NH2-terminal cysteine using m-maleimidobenzoyl N-hydroxysuccinimide ester (MBS). For the primary inoculation, 150 µg of the conjugated peptide was emulsified in complete Freund's adjuvant and injected intradermally into adult female rabbits (Harlow and Lane, 1988). Antibody production was boosted 4 wk later by the subcutaneous injection of 100 µg conjugated peptide emulsified in incomplete Freund's adjuvant. After 12 d, the animals were bled through an ear vein. The antibody titer following the first boost was then measured using the unconjugated peptide in a solid-phase ELISA (Harlow and Lane, 1988). Animals making anti-peptide antibodies were then boosted further with 100 µg of conjugated peptide at 4-wk intervals, with serum collected 2 wk after each boost. The anti-peptide antibodies were purified on a peptide affinity column of epoxy-activated Sepharose 6B (Pharmacia Fine Chemicals, Piscataway, NJ). For adsorption, the antibody was diluted 1:100 in 500 µl 0.1% Tween-20/PBS, 0.5 mg peptide added, the mixture incubated overnight at 4°C, and then diluted further in the same solution for immunostaining.

### Immunostaining

For immunocytochemistry, cells cultured overnight in a 24-well plate were fixed in 4% paraformaldehyde in 0.1 M PBS, pH 7.2, permeabilized in 0.2% Triton X-100/PBS for 15 min and blocked with 5% nonfat dry milk in PBS for 30 min at room temperature. The cells were then incubated for 60 min with the primary antibody diluted 1:1,000-1:5,000 in 1% nonfat dry milk/PBS and washed three times in PBS, each for 5 min. Incubation in a secondary biotinylated anti-rabbit antibody (Vector Labs, Burlingame, CA) was also carried out for 30 min, followed by three 5-min washes in PBS. The complexes were visualized using avidin-biotin conjugated to alkaline phosphatase (Vector Labs).

For immunofluorescence, both CHO and PC12 cells were grown on glass coverslips to 60-80% confluence and processed as described (Schweitzer and Paddock, 1990). PC12 cells were treated with 10 ng/ml NGF in medium containing serum for 4 days before staining. The cells were then fixed as described above, permeabilized in 0.1% Triton X-100/Heps-buffered saline (HBS), then incubated with anti–peptide antibody diluted 1:1,000 in 1% normal goat serum (NGS)/HBS. After washing in HBS, the cells were incubated at room temperature with goat anti–rabbit antibody conjugated to fluorescein diluted 1:100 in 1% NGS/HBS, washed again, and visualized with epifluorescence.

Double staining with WGA conjugated to Texas red and monoclonal antibodies to tubulin, secretogranin I, and synaptophysin was carried out simultaneously. The mouse antibodies were visualized by incubation with a biotinylated sheep anti-mouse antibody followed by streptavidin-Texas red (Amersham Corp.).

To identify transferrin receptors, the CHO cells were pre-incubated in serum-free medium at 37°C for 60 min to remove endogenous transferrin, incubated with 20 µg/ml human transferrin conjugated to Texas red (Molecular Probes, Eugene, OR) for an additional 30 min, rinsed quickly in cold medium without transferrin, and then fixed and the cells examined under epifluorescence.
Membrane Preparation and Cell Fractionation

Cell membranes were prepared as described previously (Liu et al., 1992b). Briefly, cells rinsed twice in cold HBS containing 5 mM MgEGTA were detached from the substrate by scraping in HBS with EGTA supplemented with 1 μg/ml leupeptin and 0.2 mM diisopropylfluorophosphate (DFP). The cells were then homogenized by repeated passage through a ball-bearing device, diluted in homogenization buffer containing 10% (v/v) glycerol, 10 mM Hepes (pH 7.4), 1% BSA, and 0.1% Triton X-100, and recentrifuged at 750 g for 5 min. The supernatant was layered onto a linear 0.6-1.6 M sucrose gradient in 10 mM Hepes for sedimentation at 30,000 rpm for 3 h in an SW41 rotor (Beckman Instruments, Palo Alto, CA) at 4°C. Fractions were collected from the bottom of the tube and stored at −70°C. The protein content was monitored using the Bradford assay (Bio-Rad Laboratories, Richmond, CA) and the radioactivity from fractions pre-loaded with [3H]norepinephrine measured in Ecolume (ICN Biomedicals, Irvine, CA) using a Beckman 3800 scintillation counter.

For velocity sedimentation through glycerol, the postnuclear supernatant was centrifuged in a SW50.1 (Beckman Instruments) at 380,000 g for 1 h at 4°C through 5-25% glycerol in FIBS containing 1% Triton X-100. Aliquots from the metrizamide and glycerol gradients were immobilized on nitrocellulose (BA-5N; Schleicher & Schuell) using a semidry electrotransfer apparatus (E&K Scientific Products Inc., Saratoga, CA).

Metabolic Labeling and Immunoprecipitation

CHO and PC12 cells at moderately high density were metabolically labeled with [35S]cysteine and methionine (Translabel; ICN Biomedicals) at 0.25 μCi/ml in cysteine- and methionine-free medium supplemented by 1% dialyzed FCS. When indicated, tunicamycin was added at 20 μg/ml to inhibit N-linked glycosylation. After labeling for 6 to 12 h, the cells were rinsed with HBS, detached from the substrate by scraping in 1% sodium deoxycholate, 1% Triton X-100, 0.2% SDS, 150 mM NaCl, 50 mM Tris, pH 7.4 (RIPA buffer) containing 20 μg/ml PMSF, and the necleus removed by centrifugation.

For immunoprecipitation, the resuspended cells were diluted to a final volume of 1 ml RIPA and incubated overnight at 4°C with affinity-purified anti-peptide antibody at a dilution of 1:1,000. The immun-anitbody complexes were precipitated by incubation for 4 h at 4°C with 10 μl 10% prewashed protein A sepharose (Sigma Chemical Co., St. Louis, MO) and the precipitates washed three times in RIPA (Edwards et al., 1988). The beads were then resuspended in 50 μl x 2 sample buffer and 25 μl separated by electrophoresis through 10% SDS-polyacrylamide containing 6 M urea. After electrophoresis at 10-25 mA, the gels were fixed in 10% acetic acid/50% methanol for 20 min, impregnated with 1 M sodium salicylate for 20 min, dried, and exposed to film at −70°C with an enhancing screen.

N-Glycanase Digestion

For N-glycanase digestion, the immunoprecipitate obtained as described above from PC12 cells metabolically labeled with [35S]cysteine and methioni- 

Immunosolubilization

Fixed S. aureus cells were pre-coated with: (a) rabbit VMAT1 anti-peptide antibody; and (b) rabbit anti-goat antisera as control by incubation with gentle rotation in 150 mM NaCl, 10 mM Hepes, pH 7.4, 1 mM EGTA, 1 mM MgCl2, 1% BSA (buffer A) for 2 h at 4°C. The cells were then washed three times in buffer A and incubated with postnuclear supernatants containing 30,000 cpm from PC12 cells pre-labeled with [3H]norepinephrine as described above. For immunosolubilization with the SV2 antibody, S. phaepostreptococcus aureus cells were pre-coated first with a rabbit anti-mouse antibody; then with (c) mouse SV2 monoclonal antibody; and (d) normal mouse serum as control. After incubation of the cell extracts with the pre-coated beads for 2 h at 4°C, the mixtures were precipitated by centrifugation at 1,000 g and the radioactivity in the supernatant determined by liquid scintillation counting. Subtraction of the radioactivity in the supernatant from the total radioactivity yielded the radioactivity in the immunoprecipitated vesicles.

Immunoelectron Microscopy

Methods for tissue preparation and immunolabeling were based on those described by Leranth and Pickel (1989). Adult male Sprague-Dawley rats (250-350 g) were anesthetized as described above with sodium pentobarbital and perfused with sodium pentobarbital, and perfused with 40 ml heparinized saline (1,000 U/ml heparin in 0.15 M NaCl) followed by 50 ml 3.75% acrolein and then by 200 ml 2% paraformaldehyde/0.1 M sodium phosphate, pH 7.4. The sections were incubated first for 30 min in 1% sodium borohydride/0.1 M sodium phosphate, pH 7.4 to remove reactive aldehydes and rinsed repeatedly in 0.1 M sodium phosphate, pH 7.4. The sections were cryo-protected for 1 h in 25% sucrose/3.5% glycerol/0.05 M sodium phosphate, pH 7.4 and rapidly freeze-thawed in chlorodifluoromethane followed by liquid nitrogen.

Sections were fixed in 2% osmium tetroxide for 60 min and flat embedded in Epon 812 between two pieces of Aclar plastic. Ultrathin sections were collected from the outer surface of the plastic-embedded tissue using an RMC ultramicrotome, counterstained with lead citrate, and examined using a Phillips 201 electron microscope.

Results

Production and Characterization of VMAT1 Antibody

Although the sequence of VMAT1 indicates an extremely hydrophobic protein with 12 predicted transmembrane domains and few antigenic regions, we synthesized a 16-amino acid peptide from the relatively hydrophilic COOH terminus and added a cysteine to the NH2 terminus of the sequence for coupling through MBS to the carrier KLH. After immunization, rabbit sera were screened for the presence of antibodies using a peptide ELISA. Animals producing antibodies to the peptide were boosted again and their sera tested further by immunostaining MPP+ resistant CHO cells transfected with the VMAT1 cDNA (Liu et al., 1992b).

The antisera from one rabbit recognized the VMAT1 protein in transfected but not wild-type CHO cells (Fig. 1). The
Figure 1. Immunostaining with an anti-peptide antibody shows a particulate cytoplasmic pattern of VMAT1 expression in transfected CHO fibroblasts. CHO cells transfected with the VMAT1 cDNA and selected in MPP+ (a and b) and untransfected wild-type CHO cells (c and d) were immunostained with an anti-peptide antibody to VMAT1 at a dilution of 1:2,000 and visualized by phase contrast (a and c) and epi-fluorescence (b and d). The transfected cells show a particulate pattern of cytoplasmic fluorescence very similar to that seen previously for pre-loaded dopamine (Liu et al., 1992a), whereas wild-type cells show no immunoreactivity. Comparison of the phase contrast and fluorescence micrographs shows that the focal concentration of fluorescence observed in transfected cells is outside of but adjacent to the nuclei. Bar, 10 μm.

perinuclear and scattered particulate cytoplasmic staining strongly resembled the distribution of intracellular dopamine observed after loading these same MPP+-resistant cells with exogenous dopamine (Liu et al., 1992a). To characterize the antibody further, we tested its ability to detect VMAT1 by Western blotting (Fig. 2). Wild-type CHO cells expressed no immunoreactive protein whereas transfected MPP+-resistant cells expressed large amounts of an ∼55-kD protein and smaller but still substantial amounts of an ∼95-kD protein. Rat pheochromocytoma PC12 cells, from which the VMAT1 cDNA originally derived, expressed small amounts of the 55-kD protein, and variable amounts of a higher molecular weight form of ∼120 kD. In both cell types the size differed from previous work indicating a protein of ∼75 kD in bovine chromaffin granules (Stern-Bach et al., 1990; Vincent and Near, 1991; Isambert et al., 1992) but the species origin of the cDNA from rat and the use of urea in the gel system may alter the electrophoretic mobility of this extremely hydrophobic protein. In addition, previous studies have concentrated on one of the two transport isoforms separated by isoelectric focusing (Stern-Bach et al., 1990). The differences in amount of VMAT1 expressed by the different cells are consistent with variations in the amount of VMAT1 mRNA previously observed in CHO transfectants and PC12 cells (Liu et al., 1992b). In addition, adsorption of the antibody with the peptide eliminated these immunoreactive species on Western blots (data not shown). Although the antisera had a titer of 1:1,000-1:2,000 and produced relatively low background staining in transfected cells, the antibody was further purified on a peptide affinity column (Pharmacia Biotech Inc.) and used at a dilution of 1:10,000-1:20,000.

To characterize the ability of the anti-peptide antibody to recognize VMAT1 in vivo, we have also used the antiserum to immunostain sections of the rat adrenal gland. Fig. 3 a shows strong staining of chromaffin cells in the adrenal medulla and no staining of cortical cells. As expected for a vesicle protein, the medullary cell immunoreactivity was principally cytoplasmic and did not include the nucleus. Adsorption with the peptide eliminated the medullary staining
The transfection of cDNAs for synaptic vesicle proteins into nonneural cells has led to their localization at a number of characteristic intracellular sites. Heterologous expression of synaptophysin and SV2 (Johnston et al., 1989; Cameron et al., 1991) and differs from the localization previously reported for synaptotagmin (Feany et al., 1993). The results further indicate that the vesicular amine transporter contains by itself the signals for sorting to the endocytic pathway and does not rely on association with another synaptic vesicle protein. Sorting to a population of acidic vesicles thus allows functional expression of the transporter in a nonneural cell line.

**Localization of VMAT1 in PC12 Cells to Large Dense Core Vesicles**

To determine the intracellular localization of VMAT1 in neuroendocrine cells that store monoamines, we have examined the distribution of the endogenous protein expressed by PC12 cells. As noted above, the anti-VMAT1 antibody recognizes the vesicular amine transporter expressed by these cells. Further, these typically round cells can be treated with NGF to induce the formation of neural processes and so facilitate intracellular localization. Immunostaining with the antibody to VMAT1 shows predominant expression of the antigen in the ends of processes (Fig. 6), with relatively little staining in the cell bodies. To determine the relationship of this immunoreactivity to dense core granules, we have stained the same cells with an antibody to secretogranin I, a soluble protein of LDCVs, and found the same pattern of distribution in the tips of processes. Thus, VMAT1 colocalizes with secretogranin I. Since previous studies have demonstrated the differential distribution of LDCVs and SLMVs in NGF-treated PC12 cells (Schweitzer and Paddock, 1990), we performed similar double-staining with antibodies to VMAT1 and the synaptic vesicle protein synaptophysin, which appears at much higher levels in SLMVs than in dense core granules (Navone et al., 1986). In contrast to secretogranin, immunostaining of NGF-treated PC12 cells with the antibody to synaptophysin showed expression predominantly in cell bodies and to a lesser extent at the ends of processes. Staining of the same cells with the anti–VMAT1 antibody indicated a distinct pattern of distribution, with most expression in the processes. Thus, the morphologic examination of PC12 cells by light microscopy indicates expression of VMAT1 in dense core granules and suggests its relative exclusion from SLMVs.

To characterize further the subcellular distribution of VMAT1 in PC12 cells, we have also fractionated the cells by equilibrium sedimentation through sucrose density gradients (Schweitzer and Kelley, 1985). The dense core granule fraction was identified by pre-loading the cells with [3H]norepinephrine (Fig. 7 A). An immunoblot of the fractions stained...
Figure 3. Adrenal medullary cells express VMAT1. Sections from the rat adrenal gland were stained with the anti-peptide antibody to VMAT1 (a) and with the same antibody after adsorption with the peptide used to generate it (b). All cells in the adrenal medulla (arrows) but none in the cortex react with the antibody. Adsorption with the peptide eliminates the medullary immunoreactivity entirely and reduces the punctate staining observed to varying degrees in the cortex. Bar, 150 μm.

with an antibody to secretogranin II indicated that this protein resides as expected in the heavier, dense core granules also pre-labeled with [3H]norepinephrine (Fig. 7 B). In contrast, an antibody to synaptophysin labeled predominantly a lighter fraction of vesicles distinct from the peak of soluble protein, with variable but substantially lower levels of expression in the dense core granule fraction. The anti-peptide antibody to VMAT1 detected the 55-kD form of the protein in the peak of LDCVs centered at fraction 6. No immunoreactive protein of this size appeared in the lighter fractions. However, the immunoreactive material migrating at ~120 kD appeared in both heavy and light membrane fractions. To determine whether this material is VMAT1 or unrelated background, we immunostained another Western blot containing fractions from the gradient with a preparation of antibody that had been adsorbed with the peptide used to generate it. Pre-adsorption with the peptide abolished the staining of both the 55- and ~120-kD bands, indicating that both of these species contain VMAT1. Thus, the endogenous vesicular amine transporter expressed by PC12 cells occurs in two forms, a low molecular weight form that appears to reside exclusively in LDCVs and a higher molecular weight form that predominates in dense fractions but also occurs in lighter membranes, possibly...
SLMVs or plasma membrane vesicles. The higher molecular weight form usually but not always (Fig. 2) predominates in PC12 cells, independent of the method of analysis (by Western blot of cell homogenates or immunoprecipitation of metabolically labeled cell extracts). However, the high molecular weight form does not simply occur as soluble protein since it had a higher density distinct from the peak of soluble protein that appeared at the top of the gradient.

Large membrane proteins, particularly those with multiple predicted transmembrane domains, have a tendency to aggregate, possibly accounting for the higher molecular weight form of VMAT1 observed in PC12 cells. However, preparation of the extracts from transfected CHO cells under the identical conditions did not yield the same species, suggesting that a modification specific to PC12 cells is responsible for this form. To characterize this modification further, we metabolically labeled both CHO and PC12 cells, immunoprecipitated VMAT1 from the postnuclear supernatant and treated the precipitates with N-glycanase to remove N-linked carbohydrate. As expected from the immunoblots, wild-type CHO cells expressed no detectable VMAT1 (Fig. 8) whereas the MPP⁺-resistant CHO transformants expressed proteins of ~55 and ~95 kD. Treatment with N-glycanase reduced both of these to a species migrating at ~40 kD. The immunoprecipitate from PC12 cells also contained small amounts of a protein of ~55 kD in addition to larger amounts of the ~120-kD protein seen on immunoblots. Interestingly, treatment of this immunoprecipitate with N-glycanase resulted in increased amounts of a ~50-kD protein. This indicated that the high molecular weight form of VMAT1 expressed in PC12 cells does not represent aggregates but rather extensive N-linked carbohydrate modification. Pulse-chase studies confirm a precursor-product relationship between the two forms (Liu, Y., and R. H. Edwards, manuscript in preparation). The failure to reduce the proteins in PC12 cells to the size obtained after digestion of the proteins expressed in CHO cells further suggests either incomplete digestion or a second modification not removed by N-glycanase. The treatment of PC12 cells with tunicamycin also showed reduction of the principal species to only ~50 kD (data not shown), suggesting that a second modification is responsible. We have identified a similar high molecular weight form of the transporter in Western blots of protein extracted from the rat adrenal gland (data not shown), indicating that this modification is not unique to PC12 cells and occurs in vivo as well.

Both Endosomes and Synaptic-like Microvesicles Contain Small Amounts of VMAT1

Quantitation of immunoblots by densitometry shows that 65% VMAT1 occurs in LDCVs and 19% in lighter fractions. This preferential localization to LDCVs differs from that of other membrane proteins that occur in both compartments. In contrast to VMAT1, 42% SV2 immunoreactive protein resides in LDCVs and 49% in lighter fractions (data not shown). To localize the VMAT1 immunoreactivity that appears in lower density fractions on the sucrose gradient, we have used additional density gradients. Light vesicle fractions from the sucrose gradient may contain endosomes, SLMVs or both. To determine whether VMAT1 occurs on endosomes as well as LDCVs, we have used sedimentation

Figure 4. VMAT1 immunofluorescence in transfected CHO fibroblasts co-localizes with the microtubule-organizing center and the Golgi complex. Stable CHO transformants expressing VMAT1 were viewed by phase contrast (a and d) and immunostained with the polyclonal rabbit VMAT1 antibody (b and e), a mouse monoclonal antibody to tubulin (c) and WGA conjugated to Texas red (f). For double staining of the two sets of cells (a-c and d-f), the VMAT1 rabbit antibody was visualized with a secondary antibody conjugated to fluorescein and the mouse anti-tubulin antibody with a secondary antibody conjugated to Texas red. The strong punctate peri-nuclear VMAT1 immunoreactivity (arrows, b) co-localizes with the microtubule organizing center (arrows, c). Additional peri-nuclear VMAT1 staining (arrows, e) co-localizes with wheat germ agglutinin (arrows, f). Bar, 10 μm.
Figure 5. VMAT1 immunofluorescence co-localizes with a population of recycling endocytic vesicles. Stable CHO transformants expressing VMAT1 were pre-incubated with human transferrin conjugated to Texas red for 30 min and immunostained for VMAT1. Visualization of VMAT1 immunoreactivity with a secondary antibody conjugated to fluorescein (a) shows a virtually identical pattern of labeling to the transferrin receptor (b) as a marker of recycling endocytic vesicles. Bar, 10 μm.

Discussion

Using an antibody raised against the COOH terminus of the vesicular amine transporter expressed in the adrenal gland, we have localized the protein in transfected CHO fibroblasts to a population of recycling endocytic vesicles. By immunofluorescence, the transporter co-localizes with recycling transferrin receptors. In addition, peri-nuclear staining co-localizes with markers for the microtubule organizing.
Figure 6. Endogenous VMAT1 immunofluorescence in PC12 cells co-localizes with LDCVs rather than SLMVs. PC12 cells were treated with NGF (10 ng/ml) for 4 d before staining. Three sets of cells (a-c, d-f and g-i) were viewed by phase contrast (a, d, and g), stained with the rabbit VMAT1 antibody (b and e) and the same antibody after adsorption with the peptide used to generate it (h) and the reactions visualized with a secondary antibody conjugated to fluorescein. The same cells were double-stained with a mouse monoclonal antibody to secretogranin I (c and i) and synaptophysin (f). VMAT1 appears predominantly at the tips of neuritic processes rather than the cell body and control serum shows no immunoreactivity (h). Further, VMAT1 co-localizes with secretogranin I (c), a marker for LDCVs. In contrast, VMAT1 staining appears distinct from synaptophysin (f), a marker for SLMVs. Bar, 10 μm.

center and the Golgi complex. The results account for the detection of vesicular amine transport activity in membranes prepared from the stable VMAT1 transformants even though these cells lack a known secretory compartment for regulated release such as synaptic vesicles or LDCVs. Transport activity depends on a H⁺-electrochemical gradient across the vesicle membrane and several of the compartments in which the transporter apparently occurs such as the endosomes and Golgi complex contain a vacuolar H⁺-ATPase that can generate such a gradient (Rudnick, 1986; Forgac, 1989).

The sorting of VMAT1 in CHO cells strongly resembles that of other synaptic vesicle proteins such as synaptophysin when they are expressed in fibroblasts (Johnston et al., 1989; Cameron et al., 1991). These observations indicate that the vesicular amine transporter contains its own signals for endocytosis. Recycling of the transporter from the cell surface after exocytotic fusion therefore does not require association with other synaptic vesicle proteins. Indeed, the expression of other synaptic vesicle proteins in CHO fibroblasts appears to result in distinct patterns of localization. In contrast to synaptophysin, synaptotagmin targets to the plasma membrane and SV2 targets to a population of vesicles that excludes the transferrin and low density lipoprotein receptors as markers of the recycling endosomal pathway (Feany et al., 1993). Interestingly, the vesicular amine transporter resembles synaptophysin more than these two other synaptic vesicle proteins in terms of targeting in CHO cells even though
Figure 7. Distribution of VMAT1 by equilibrium sucrose density gradient fractionation of PC12 cells. PC12 cells were pre-loaded overnight with \[^{3}H\]norepinephrine and a postnuclear supernatant loaded onto a 0.6-1.6 M continuous sucrose gradient, with fractions collected from the bottom. (A) Distribution of total protein on the gradient shows two peaks, one centered at fraction 6 and the other at fraction 18. Radioactivity also accumulates in a peak centered at fraction 6 that presumably contains LDCVs. (B) Western blot analysis of the same fractions shown in A for VMAT1, secretogranin II, and synaptophysin, as described in Fig. 2. VMAT1 localizes with secretogranin to LDCVs whereas synaptophysin occurs predominantly in lighter membranes (but not soluble proteins as shown in A). VMAT1 occurs in two forms, the ~55-kD form also seen in CHO cells and a higher molecular weight form not seen in CHO cells. The high molecular weight form predominates in the heavier membrane fractions and is the only form seen in lighter fractions.

Figure 8. VMAT1 contains variable but substantial amounts of N-linked glycosylation. Wild type and transfected (MPP\(^{+}\)) CHO cells and PC12 cells were metabolically labeled with \[^{35}S\]cysteine and methionine overnight and the postnuclear supernatants immunoprecipitated with the VMAT1 antibody. The immunoprecipitates were then digested without and with N-glycanase and separated by electrophoresis as described in Fig. 2. Wild-type CHO cells contain no immunoprecipitated protein whereas stable VMAT1 transformants contain the ~55- and ~100-kD proteins seen on Western blots. Treatment with N-glycanase reduces the majority of these species to ~40 kD. The unusually high mobility of this protein both before and particularly after N-glycanase digestion presumably reflects the anomalous electrophoretic behavior of an extremely hydrophobic protein rather than degradation. In PC12 cells, the high molecular weight form predominates over a faint but detectable band at ~55 kD and is reduced to ~50 kD by N-glycanase (arrows).

Figure 9. VMAT1 occurs predominantly on fractions corresponding to LDCVs. A post-nuclear supernatant of PC12 cells pre-labeled with \[^{3}H\]norepinephrine was fractionated by sedimentation through metrizamide and the fractions collected from the bottom. The upper panel shows the percentage of metrizamide in each fraction and the middle panel the total protein and radioactivity in each fraction. The lower panel shows the densitometric quantitations of VMAT1, secretogranin II (SgII), transferrin receptor (TfR), and synaptophysin (P38) immunoreactivity from dot blots stained with the appropriate antibodies. The immunoreactivity for each of the fractions stained with one antibody was added and the percentage of the total in each fraction is shown. Secretogranin II and \[^{3}H\]norepinephrine label a broad peak of LDCVs centered at fraction 7. VMAT1 labels this same broad peak but also occurs in lighter membrane fractions containing the transferrin receptor and synaptophysin as markers for endosomes and SLMVs respectively.
sorting of the transporter and synaptophysin differ strongly in neuro-endocrine PC12 cells.

In PC12 cells, previous work using the measurement of transport activity has suggested localization of the vesicular amine transporter in LDCVs (Bauerfeind et al., 1993). We have now used an antibody to identify preferential localization of the transport protein in LDCVs both by immunofluorescence analysis of doubly stained cells and by cell fractionation using a variety of gradients. Immunoelectron microscopy of adrenal medullary cells also shows staining of chromaffin granules but the paucity of SLMVs in these cells makes it difficult to exclude a presence in that compartment as well. In addition, PC12 cells may contain more LDCVs than SLMVs but the substantial expression of other synaptic vesicle membrane proteins such as SV2 and synaptotagmin in both compartments (Buckley et al., 1985; Walch-Solimena et al., 1993) or such as synaptophysin predominantly in SLMVs (Navone et al., 1986) makes the preferential localization of the amine transporter in LDCVs unique. The biogenesis of LDCVs and synaptic vesicles differ in several important respects. LDCVs in neurons and secretory granules in endocrine cells originate from the trans-Golgi network (Burgess and Kelly, 1987; Trimble et al., 1991). Selected proteins such as neural peptides sort into this regulated secretory pathway through poorly characterized mechanisms. After fusion with the plasma membrane, components of the dense core granule membrane may recycle to the Golgi complex for refilling and re-release. In contrast, synaptic vesicles from neurons or SLMVs from endocrine cells appear to originate from early endosomes (Kelly, 1991). The synaptic vesicle protein synaptophysin occurs at only very low levels in dense core granules (Navone et al., 1986), suggesting that synaptic vesicles do not derive from recycled granule membrane components (Cutler and Cramer, 1990). Rather, synaptophysin travels directly to the plasma membrane in the constitutive secretory pathway and synaptic vesicles appear to bud off early endosomes (Clift-OG'Grady et al., 1990; Regnier-Vigouroux et al., 1991). Thus, LDCVs derive from the regulated secretory pathway and SLMVs from the constitutive secretory pathway. The mechanism for sorting of proteins into these two pathways remains unclear. However, membrane proteins such as synaptophysin serve to distinguish SLMVs from LDCVs and may enable dissection of the relevant sorting signals. On the other hand, LDCVs contain soluble proteins and membrane-associated proteins absent from the constitutive pathway and synaptic vesicles. These proteins may sort into the regulated pathway through aggregation but a clear sorting signal has not been identified (Burgess and Kelly, 1987). However, VMAT1 now provides a clear membrane protein uniquely associated with LDCVs and not SLMVs.

In addition to neural peptides, several membrane proteins localize preferentially to LDCVs rather than to synaptic vesicles or SLMVs. These proteins include cytochrome b561 that mediates the reduction of intravesicular ascorbate, the processing enzyme peptidylglycine α-amidating monooxygenase (PAM), and dopamine β-hydroxylase (DBH). DBH does not contain a membrane-spanning domain but associates with the lumenal face of the vesicle membrane, excluding the possibility of sorting signals on the cytoplasmic surface of the vesicle. PAM occurs in two forms, one soluble and the other attached to the vesicle membrane at the COOH-terminus (Milgram et al., 1993, 1994). The two
Figure 12. VMAT1 localizes to chromaffin cells exposed to the reagents for immunolabeling. Electron micrographs of chromaffin cells in the adrenal medulla (a) immunolabeled for VMAT1 and (b) not exposed to the immunoreagents. The most prominent immunolabeling in (a) occurs in chromaffin granules (curved arrows). Immunoreaction product is notably absent from the chromaffin cell nucleus (N) and from axon terminals (t) of adjacent neurons. In (b), the pattern of immunolabeling seen in (a) is absent from tissue not exposed to the reagents. (L, lysosome; m, mitochondria. Bar, 2 μm.)
Figure 13. VMAT1 immunoreactivity localizes to chromaffin granules and not the synaptic vesicles of adjacent neuronal processes. (a) Electron micrograph showing immunoperoxidase reaction product for VMAT1 in most chromaffin granules (curved arrows). Less conspicuous labeling for VMAT1 occurs in smaller vesicles in the trans-Golgi network (large arrows) and in both endoplasmic reticulum and free polyribosomes (small arrows). In contrast, immunoreaction product for VMAT1 cannot be detected in mitochondria (m) or early Golgi apparatus (G). (b) Higher magnification electron micrograph of the boxed region in Fig. 12 a. Intense labeling for VMAT1 occurs in a large population of chromaffin granules (curved arrows), but cannot be detected in either the small clear vesicles (scv) or the dense core vesicles (dcv) of adjacent axon terminals. (N, nucleus of chromaffin cell; open arrow, outer membrane of chromaffin cell. Bar, 0.5 μm.)
forms differ in their trafficking through the cell but both sort to LDCVs, indicating the importance of interactions within the interior of the vesicle for targeting to this pathway. It also remains unclear whether PAM occurs in synaptic vesicles. Cytochrome b561 has six predicted transmembrane domains (Perin et al., 1988; Kent and Fleming, 1990) and thus differs from DBH and PAM in its membrane topology. Although the cytochrome appears in both LDCVs and synaptic vesicles (Walch-Solimena et al., 1993), it is predominantly localized to the SLMV peak, suggesting that the vesicular amine transporter may be a more specific integral membrane protein for the regulated secretory pathway.

The transporter may resemble soluble proteins that are specific for LDCVs and sort into the pathway through lumenal domains. Recent evidence suggests that interactions of this type may confer sorting to the apical pathway in polarized epithelial cells (Fiedler et al., 1994). The identification of extensive N-linked glycosylation on the transporter expressed in PC12 cells but not fibroblasts further raises the possibility of interaction with lectins that may play a role in polarized targeting. However, sorting may also occur by interaction of the transmembrane and cytoplasmic domains with specific gradients of a protein sorting machinery.

Velocity gradient centrifugation through glycerol indicates that a relatively small proportion of the total vesicular amine transporter occurs in SLMVs. The small amounts of protein may account for the failure to observe vesicular amine transport activity in SLMVs prepared on sucrose density gradients, particularly when adjacent fractions containing endosomes express substantial transport activity (Bauerfeind et al., 1993). The transporter could appear in SLMVs by two distinct mechanisms. First, incomplete sorting to the regulated pathway could result in some of the transport protein reaching the cell surface through the constitutive pathway. Second, the transporter could arrive at the plasma membrane following the fusion of LDCVs. In both cases, the transporter may sort into SLMVs after endocytosis. Although the amine transporter in SLMVs represents a small fraction of the total transporter in PC12 cells, neurons in the central nervous system appear to store monoamines in small synaptic vesicles (Smith, 1972; Thureson-Klein, 1983). The identification of small amounts of the adrenal transporter in SLMVs raises the possibility that central neurons use a similar pathway to sort the transporter into synaptic vesicles. Neurons may simply increase the efficiency of sorting to this pathway. Alternatively, the vesicular amine transporter expressed in the brain may contain signals different from the adrenal transporter that increase the efficiency of this sorting.

We thank W. Huttner and P. Rosa for the generous gift of antibodies, S. Greene, and R. B. Kelly for thoughtful discussion, and B. Vigil with help in preparing the manuscript.

This research was supported by the National Institute of Mental Health, March of Dimes, and National Alliance for Research on Schizophrenia and Affective Disorders.

Received for publication 19 July 1994 and in revised form 13 September 1994.

References


